Nurix Therapeutics NRIX
NASDAQ NRIX
$23.71 +0.03 (+0.15%)
At close: Sep 30, 2026 · 4:00 PM EDT

Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026)

Updated

Nurix Therapeutics (NRIX) reported EBITDA Margin of -1016.80% for fiscal Q2 2026 (quarter ended May 31, 2026), down 912.20 percentage points from -104.59% a year earlier but up 427.52 percentage points from the prior quarter.

Analysis

Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026) Analysis & Trends

Over the twelve months ended May 31, 2026, Nurix Therapeutics' EBITDA Margin came in at -958.98%, down 709.02 percentage points year-over-year; for FY2025 (ended Nov 30, 2025), it was -329.75%, up 43.69 percentage points from FY2024.

  • EBITDA Margin has a five-year change of +22.57 percentage points (FY2020 to FY2025).
  • By fiscal year, EBITDA Margin came in at -373.44% in FY2024 (-181.81 pp), -191.63% in FY2023 (+270.53 pp), -462.16% in FY2022 (-75.31 pp) and -386.84% in FY2021 (-34.53 pp).
  • Five-year quarterly EBITDA Margin spans a low of -1444.32% in fiscal Q1 2026 and a high of -81.07% in fiscal Q2 2023.
  • Year over year, EBITDA Margin has now declined in each of the last four quarters, with an average year-over-year change of -381.83 percentage points over the last eight quarters.
  • The high point for year-over-year EBITDA Margin in five years was fiscal Q4 2023 (a gain of 407.66 percentage points); the low point was fiscal Q1 2026 (a drop of 1116.39 percentage points).
  • Per Business Quant data, the three fiscal quarters before Q2 2026 came in at -1444.32% (Q1 2026), -596.41% (Q4 2025) and -1131.96% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 35.95%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 49.01%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 6.02%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 33.11%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 39.10%
10 Nurix Therapeutics 2.45 Bn 448.58 Mn - -1,016.80%
Historic Data

Historic Data

Download Data
DateValue
May 31, 2026 -1,016.80%
Feb 28, 2026 -1,444.32%
Nov 30, 2025 -596.41%
Aug 31, 2025 -1,131.96%
May 31, 2025 -104.59%
Feb 28, 2025 -327.94%
Nov 30, 2024 -467.54%
Aug 31, 2024 -414.82%
May 31, 2024 -382.15%
Feb 29, 2024 -260.32%
Nov 30, 2023 -286.30%
Aug 31, 2023 -206.10%
May 31, 2023 -81.07%
Feb 28, 2023 -324.79%
Nov 30, 2022 -693.96%
Aug 31, 2022 -419.03%
May 31, 2022 -388.51%
Feb 28, 2022 -433.98%
Nov 30, 2021 -502.79%
Aug 31, 2021 -276.01%
API Access

Nurix Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NRIX&period=max&api_key=YOUR_API_KEY